A Phase 1/2 Study of Carbon Ion Radiation Therapy With Concurrent Chemotherapy for Locally Advanced Uterine Cervical Squamous Cell Carcinoma (Protocol 1302)

Okonogi, Noriyuki; Wakatsuki, Masaru; Kato, Shingo; Karasawa, Kumiko; Miyasaka, Yasuhiro; Murata, Hiroto; Nakano, Takashi; Kamada, Tadashi; Shozu, Makio

doi:10.1016/j.ijrobp.2019.02.042

Cited by 14 publications

(21 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, CIRT or chemo-CIRT seems to be another promising strategy for LAAC of the uterine cervix. Although we previously demonstrated that chemo-CIRT for LAAC of the uterine cervix is associated with a longterm survival benefit using a propensity score-matched analysis, especially in stage IIIB disease [25]. In terms of prognostic factors based on the clinical outcomes of the present study, concurrent uses of chemotherapy did not affect LC, DSF, or OS rate.…”

Section: Discussioncontrasting

confidence: 59%

“…Due to these advantages, CIRT has been applied to various types of malignancies, including uterine cervical cancer [21]. We have investigated the clinical significance of CIRT for locally advanced AC (LAAC) of the uterine cervix for decades [22][23][24][25]. Wakatsuki et al reported that the 5-year LC rate for CIRT was 55% [22].…”

Section: Introductionmentioning

confidence: 99%

“…The two-year LC and overall survival (OS) rates were 71% and 88%, respectively [24]. We recently reported the long-term significance of concurrent weekly cisplatin and CIRT (chemo-CIRT) for LAAC of the uterine cervix in a propensity score-matched analysis [25]. Thus, chemo-CIRT for LAAC is a promising therapeutic strategy.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Multi-institutional Retrospective Analysis of Carbon-ion Radiotherapy for Patients with Locally Advanced Adenocarcinoma of the Uterine Cervix

Okonogi¹,

Ando²,

Murata³

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

The clinical significance of carbon-ion radiotherapy (CIRT) for adenocarcinoma (AC) of the uterine cervix has been assessed in several single-institutional studies. To validate the significance, we conducted a multi-institutional survey of CIRT for locally advanced AC (LAAC) of the uterine cervix. We retrospectively analyzed the clinical outcomes of patients with stage IIB–IVA LAAC of the uterine cervix who underwent chemo-CIRT or CIRT alone between April 2010 and April 2016. Patients received 74.4 Gy (relative biological effectiveness [RBE]) in 20 fractions of CIRT or 55.2 Gy (RBE) in 16 fractions of CIRT plus 3 sessions of brachytherapy. Patients aged ≤70 years with adequate bone marrow and organ function were administered cisplatin weekly (40 mg/m2 per week for up to 5 weeks). Fifty-five patients were enrolled in this study. The median follow-up period was 67.5 months. The 5-year overall survival (OS) and local control (LC) rates were 68.6% and 65.2%, respectively. Multivariate analysis showed that the initial tumor response within 6 months was significantly associated with LC and OS. The present study represents promising outcomes of CIRT or chemo-CIRT for LAAC of the uterine cervix, especially in the cases showing initial rapid regression of the tumor.

show abstract

Section: Discussioncontrasting

confidence: 59%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Multi-institutional Retrospective Analysis of Carbon-ion Radiotherapy for Patients with Locally Advanced Adenocarcinoma of the Uterine Cervix

Okonogi¹,

Ando²,

Murata³

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…At our institution, the National Institute of Radiological Sciences (NIRS) in Japan, C-ion RT has been used to treat various types of malignancies since 1994 [8]. We previously reported the safety and effectiveness of C-ion RT for gynaecological tumours [9][10][11][12][13][14][15][16]. Notably, C-ion RT showed significant outcomes for radioresistant tumours such as adenocarcinoma of the uterus cervix or gynaecological malignant melanoma [12,15,17].…”

Section: Introductionmentioning

confidence: 99%

Pelvic insufficiency fractures following carbon-ion radiotherapy for uterine carcinomas

Miyasaka

Okonogi

Fukahori

et al. 2021

Radiotherapy and Oncology

Self Cite

View full text Add to dashboard Cite

“…Recently, in photon therapy, concurrent chemoradiotherapy has become standard treatment for several types of cancer in expectation of a sensitizing effect of RT and preventing micrometastasis throughout the body (14)(15)(16). RT with C-ions, combined with anticancer drugs has been performed for uterine cervical cancer, pancreatic cancer, and malignant melanoma of head and neck (2,8,(17)(18)(19) for example. The radiosensitizing effect of C-ion beams combined with anticancer drugs has also been reported in vitro, with high LET (70 keV/μm or higher) C-ion beams (20,21).…”

mentioning

confidence: 99%

Differences in Linear Energy Transfer Affect Cell-killing and Radiosensitizing Effects of Spread-out Carbon-ion Beams

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background/Aim: The cell-killing and radiosensitizing effects of carbon-ion (C-ion) beams with low linear energy transfer (LET) are underexplored. We aimed to demonstrate the cell-killing effects of 60 Co gamma rays and Cion beams at various LET values and the radiosensitizing effect of C-ion beams at various LET and cisplatin levels. Materials and Methods: Human uterine cervical cancer cells were irradiated with 60 Co gamma rays and C-ion beams at different levels of LET, with and without cisplatin treatment. Results: Low-LET C-ion beams had a superior cell-killing effect compared to 60 Co gamma rays. Survival curves under low-LET C-ion beams were more similar to that of 60 Co gamma rays than that of high-LET C-ion beams. Cisplatin significantly reduced cell survival after 1, 2, and 3 Gy C-ion beam irradiations at LET values of 13/30/70 keV/μm, 13/30 keV/μm, and 13 keV/μm, respectively. Conclusion: Low-LET C-ion beams combined with cisplatin have higher radiosensitizing effects than high-LET C-ion beams. Carbon-ion radiotherapy (C-ion RT) was initiated in 1994 to treat various cancer types, and favorable treatment outcomes have been reported (1-10). These outcomes are due to its localizing properties and more significant biological advantages than X-ray RT, including distal tail-off due to the Bragg peak, a sharp lateral penumbra, and higher relative biological effectiveness (RBE) due to high linear energy transfer (LET) in the Bragg peak (1, 11, 12). Additionally, C-ion beams with high LET have a superior cell-killing effect against radioresistant and hypoxic cells (13).

show abstract

A Phase 1/2 Study of Carbon Ion Radiation Therapy With Concurrent Chemotherapy for Locally Advanced Uterine Cervical Squamous Cell Carcinoma (Protocol 1302)

Cited by 14 publications

References 30 publications

Multi-institutional Retrospective Analysis of Carbon-ion Radiotherapy for Patients with Locally Advanced Adenocarcinoma of the Uterine Cervix

Multi-institutional Retrospective Analysis of Carbon-ion Radiotherapy for Patients with Locally Advanced Adenocarcinoma of the Uterine Cervix

Pelvic insufficiency fractures following carbon-ion radiotherapy for uterine carcinomas

Differences in Linear Energy Transfer Affect Cell-killing and Radiosensitizing Effects of Spread-out Carbon-ion Beams

Contact Info

Product

Resources

About